- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06495996
De Protrieve PROTECTOR-studie (PROTECTOR)
PROTECTOR: Evaluatie van de veiligheid en effectiviteit van de Protrieve Sheath bij het voorkomen van klinisch significante intraprocedurele longembolie door embolische bescherming te bieden in de IVC tijdens tromboctomieprocedures ter behandeling van DVT
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The primary study objective is to evaluate the safety and effectiveness of the Protrieve Sheath in preventing clinically significant intraprocedural pulmonary embolism by providing embolic protection in the IVC during thrombectomy procedures to treat DVT.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Newport Beach, California, Verenigde Staten, 92663
- Hoag Hospital
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510
- Yale University
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33176
- Baptist Health South Florida
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46204
- IU Health Methodist Hospital
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21218
- MedStar Union Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Beth Israel Deaconess Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89102
- University Medical Center Southern Nevada
-
-
New Jersey
-
Englewood, New Jersey, Verenigde Staten, 07631
- Englewood Hospital
-
-
New York
-
New York, New York, Verenigde Staten, 10016
- NYU Langone Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Allegheny General Hospital
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Vanderbilt University Medical Center
-
-
Texas
-
Galveston, Texas, Verenigde Staten, 77555
- University of Texas Medical Branch
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas MD Anderson Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Verenigde Staten, 26506
- West Virginia University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Age ≥ 18 years
-
Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE:
- Bilateral iliofemoral DVT
- Clot extending into or located in the IVC
- In-stent thrombosis
- Presence of thrombosed IVC filter
- Other features that the investigator deems put the subject at elevated risk for thromboembolism
-
Willing and able to provide informed consent
Exclusion Criteria:
- Current symptomatic PE
- Known anatomic inability to place Protrieve device via jugular vein access site
- Presence of clot extending to the IVC-Right Atrial junction or in the SVC
- Subject is pregnant
- Severe allergy to iodinated contrast agents that cannot be mitigated
- INR > 1.7 if not currently on anticoagulation therapy, platelets < 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin < 8.0 g/dL
- Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents
- Subject is participating in another study that may interfere with this study
- Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
- Subject has previously completed or withdrawn from this study
- Limb-threatening circulatory compromise (e.g., phlegmasia)
- Uncontrolled severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105mmHg)
- Severe allergy, hypersensitivity to, or thrombocytopenia from heparin
- Inability to provide therapeutic anticoagulation per Investigator discretion
- Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
- Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Protrieve Sheath
The Protrieve Sheath is intended for embolic protection in the inferior vena cava (IVC) to prevent clinically significant intraprocedural pulmonary embolism during mechanical thrombectomy procedures in patients with high risk of embolization. |
Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary Effectiveness Measure:
Tijdsspanne: 24 Hours (+-12 Hours)
|
a. Clinically significant PE |
24 Hours (+-12 Hours)
|
|
Primary Safety Measure:
Tijdsspanne: 24 Hours (+-12 Hours)
|
|
24 Hours (+-12 Hours)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Capture of Thromboembolic Material
Tijdsspanne: 24 Hours (+-12 Hours)
|
a. Capture and removal of thromboembolic material in the Protrieve funnel, as assessed by proportion of study cases where any material was either entrapped in the funnel or removed via Protrieve |
24 Hours (+-12 Hours)
|
|
Device Success
Tijdsspanne: 24 Hours (+-12 Hours)
|
b. Device success, defined as successful delivery, deployment, and retrieval of the Protrieve device without complications |
24 Hours (+-12 Hours)
|
|
Venous Access Routes
Tijdsspanne: 24 Hours (+-12 Hours)
|
c. Thrombectomy via supplementary venous access routes |
24 Hours (+-12 Hours)
|
|
Estimated Percentage of the Protrieve Funnel Obstructed
Tijdsspanne: 24 Hours (+-12 Hours)
|
d. Estimated percentage of the Protrieve funnel obstructed by clot, as observed by visual inspection or imaging |
24 Hours (+-12 Hours)
|
|
Blood Transfusions
Tijdsspanne: 24 Hours (+-12 Hours)
|
e. Blood transfusions associated with Protrieve Sheath access site bleeding |
24 Hours (+-12 Hours)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Ripal Gandhi, MD, Baptist Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 23-003
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .